Clinton Snow
Director/Board Member en ICETANA LIMITED .
Perfil
Clinton Snow is currently a Non-Executive Director at Dimerix Ltd., PolyActiva Pty Ltd., and iCetana Ltd.
He completed his undergraduate degree at the University of Melbourne.
Cargos activos de Clinton Snow
Empresas | Cargo | Inicio |
---|---|---|
ICETANA LIMITED | Director/Board Member | 08/02/2022 |
DIMERIX LIMITED | Director/Board Member | 01/05/2023 |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Director/Board Member | - |
Formación de Clinton Snow.
University of Melbourne | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
DIMERIX LIMITED | Health Technology |
ICETANA LIMITED | Technology Services |
Empresas privadas | 1 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Bolsa de valores
- Insiders
- Clinton Snow